Challenges and progress in the development of a serogroup B meningococcal vaccine

被引：2
|
作者：
Lewis, Susan [1 ]
Sadarangani, Manish [1 ]
Hoe, J. Claire [1 ]
Pollard, Andrew J. [1 ]
机构：
[1] Univ Oxford, Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Dept Paediat,Oxford Vaccine Grp, Oxford OX3 7LJ, England
来源：
EXPERT REVIEW OF VACCINES | 2009年 / 8卷 / 06期
关键词：
5CVMB; meningococcal disease; outer membrane protein; outer membrane vesicle vaccine; serogroup B; MEMBRANE-VESICLE VACCINE; INNER-CORE LIPOPOLYSACCHARIDE; MENINGITIDIS GROUP-B; H-BINDING PROTEIN; SYNERGISTIC BACTERICIDAL ACTIVITY; NEISSERIA-LACTAMICA PROTECTS; HUMAN-ANTIBODY RESPONSES; HUMAN SERUM ANTIBODIES; NEW-ZEALAND; ESCHERICHIA-COLI;
D O I：
10.1586/ERV.09.30
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Serogroup B meningococci cause the majority of the meningococcal disease burden in developed countries. Production of an effective and safe vaccine for serogroup B organisms has been hampered by the poor immunogenicity of the capsular polysaccharide that defines this group of bacteria. Previous efforts have focused on outer membrane vesicle vaccines, which have been implemented successfully during clonal outbreaks. However, the search for a universal vaccine against endemic polyclonal serogroup B meningococcal disease continues. In this review, we have highlighted recent development of outer membrane vesicle vaccines and progress in the evaluation of recombinant outer membrane protein vaccines.
引用
收藏
页码：729 / 745
页数：17
相关论文
共 50 条
  • [1] An effective serogroup B meningococcal vaccine
    Dominguez, Francisco
    Menendez, Jorge
    Ochoa, Rolando
    VACCINE, 2006, 24 (49-50) : 7025 - 7026
  • [2] Recent Progress in the Prevention of Serogroup B Meningococcal Disease
    Feavers, Ian M.
    Maiden, Martin C. J.
    CLINICAL AND VACCINE IMMUNOLOGY, 2017, 24 (05)
  • [3] Neisseria meningitidis serogroup B vaccine development
    Caesar, Nicole M.
    Myers, Kenneth A.
    Fan, Xin
    MICROBIAL PATHOGENESIS, 2013, 57 : 33 - 40
  • [4] Meningococcal Group B Vaccine For The Prevention Of Invasive Meningococcal Disease Caused By Neisseria meningitidis Serogroup B
    Rivero-Calle, Irene
    Francis Raguindin, Peter
    Gomez-Rial, Jose
    Rodriguez-Tenreiro, Carmen
    Martinon-Torres, Federico
    INFECTION AND DRUG RESISTANCE, 2019, 12 : 3169 - 3188
  • [5] Serogroup B meningococcal disease in persons previously vaccinated with a serogroup B meningococcal vaccine - United States, 2014-2019
    Reese, Heather E.
    McNamara, Lucy A.
    Vianzon, Vianca
    Blain, Amy
    Topaz, Nadav
    Many, Patricia
    Barbeau, Bree
    Albertson, Justin P.
    Lam, Esther
    DeBolt, Charla
    Zaremski, Elizabeth F.
    Hannagan, Susan E.
    Evans, Derek J.
    Hariri, Susan
    Wang, Xin
    Granoff, Dan M.
    Mbaeyi, Sarah
    VACCINE, 2021, 39 (52) : 7655 - 7660
  • [6] Diversity of greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine
    Tzanakaki, Georgina
    Hong, Eva
    Kesanopoulos, Konstatinos
    Xirogianni, Athanasia
    Bambini, Stefania
    Orlandi, Luca
    Comanducci, Maurizio
    Muzzi, Alessandro
    Taha, Muhamed-Kheir
    BMC MICROBIOLOGY, 2014, 14
  • [7] Effectiveness of a Serogroup B and C Meningococcal Vaccine Developed in Cuba
    Ochoa-Azze, Rolando F.
    Garcia-Imia, Luis
    Verez-Bencomo, Vicente
    MEDICC REVIEW, 2018, 20 (03) : 22 - 29
  • [8] A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
    Martin, Natalie G.
    Snape, Matthew D.
    EXPERT REVIEW OF VACCINES, 2013, 12 (08) : 837 - 858
  • [9] Serogroup B meningococcal vaccines-an unfinished story
    Sadarangani, Manish
    Pollard, Andrew J.
    LANCET INFECTIOUS DISEASES, 2010, 10 (02) : 112 - 124
  • [10] Multivalent meningococcal serogroup B vaccines: challenges in predicting protection and measuring effectiveness
    Poolman, Jan T.
    Richmond, Peter
    EXPERT REVIEW OF VACCINES, 2015, 14 (09) : 1277 - 1287
12345